fluorouracil has been researched along with Retinal Detachment in 28 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Retinal Detachment: Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of a combination of 5-fluorouracil (5FU) and low-molecular-weight heparin (LMWH) in the treatment of unselected rhegmatogenous retinal detachment (RRD) undergoing primary vitrectomy." | 9.12 | Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. ( Bunce, C; Charteris, DG; McGurn, D; Wickham, L; Wong, D, 2007) |
| "To determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR)." | 9.11 | A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Groenewald, C; Wong, D, 2004) |
| "To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery." | 9.09 | Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Khaw, PT; Kon, CH; Wong, D, 2001) |
| "To determine the potential of an intravitreal sustained release naproxen and 5-fluorouracil (NA/5-FU) codrug for the treatment of experimental proliferative vitreoretinopathy (PVR) in a model for trauma associated tractional retinal detachment (TRD)." | 7.72 | An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. ( Ashton, P; Cardillo, JA; Costa, RA; Farah, ME; Jorge, R; Kuppermann, B; Melo, LA; Mitre, J; Morales, PH, 2004) |
| " 5-fluorouracil, a synthetic pyrimidine analog, is a potent inhibitor of fibroblast proliferation in cell culture and an animal model of tractional retinal detachment." | 7.67 | 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. ( Blumenkranz, M; Hernandez, E; Norton, EW; Ophir, A, 1984) |
| "On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued." | 5.72 | [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022) |
| "To determine the efficacy of a combination of 5-fluorouracil (5FU) and low-molecular-weight heparin (LMWH) in the treatment of unselected rhegmatogenous retinal detachment (RRD) undergoing primary vitrectomy." | 5.12 | Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. ( Bunce, C; Charteris, DG; McGurn, D; Wickham, L; Wong, D, 2007) |
| "To determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR)." | 5.11 | A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Groenewald, C; Wong, D, 2004) |
| "To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery." | 5.09 | Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Khaw, PT; Kon, CH; Wong, D, 2001) |
| "To determine the potential of an intravitreal sustained release naproxen and 5-fluorouracil (NA/5-FU) codrug for the treatment of experimental proliferative vitreoretinopathy (PVR) in a model for trauma associated tractional retinal detachment (TRD)." | 3.72 | An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. ( Ashton, P; Cardillo, JA; Costa, RA; Farah, ME; Jorge, R; Kuppermann, B; Melo, LA; Mitre, J; Morales, PH, 2004) |
| "To test the efficacy of a biodegradable device for the intravitreal sustained release of fluorouracil in the treatment of tractional retinal detachment due to proliferative vitreoretinopathy." | 3.69 | Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. ( Cousins, SW; Davis, PA; Hernandez, E; O'Grady, GE; Rubsamen, PE, 1994) |
| "Six patients, each with one eye that had previously undergone circular buckling surgery for the repair of retinal detachment before or followed by cataract extraction with or without intraocular lens implantation, underwent trabeculectomy with 5-fluorouracil (5-FU) for intractable glaucoma." | 3.68 | Trabeculectomy with 5-fluorouracil subsequent to circular buckling operation and cataract extraction. ( Ophir, A; Ticho, U, 1992) |
| "The rate of retinal detachment in fellow control eyes of rabbits following fibroblast administration is progressively lower with increased dose of 5-Fluorouracil in the test eyes." | 3.68 | Further observations on the prevention of experimental proliferative vitreo-retinopathy by 5-fluorouracil. ( Ophir, A, 1991) |
| " 5-fluorouracil, a synthetic pyrimidine analog, is a potent inhibitor of fibroblast proliferation in cell culture and an animal model of tractional retinal detachment." | 3.67 | 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. ( Blumenkranz, M; Hernandez, E; Norton, EW; Ophir, A, 1984) |
| "Fluorouracil effectively inhibits epiretinal membrane formation and traction retinal detachment after vitrectomy surgery." | 3.66 | Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. ( Anderson, DH; Erickson, PA; Fisher, SK; Guerin, CJ; Lewis, GP; O'Donnell, JJ; Stern, WH, 1983) |
| "On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued." | 1.72 | [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022) |
| "5-Fluorouracil (5-FU) is a potent inhibitor of the proliferation of fibroblasts, the main cell mediators of scar formation." | 1.28 | Effects of 5-fluorouracil on proliferating fibroblasts in vivo. ( Ophir, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.00) | 18.7374 |
| 1990's | 6 (21.43) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Schaub, F | 2 |
| Schiller, P | 2 |
| Hoerster, R | 2 |
| Kraus, D | 2 |
| Holz, FG | 1 |
| Guthoff, R | 1 |
| Agostini, H | 1 |
| Spitzer, MS | 1 |
| Wiedemann, P | 2 |
| Lommatzsch, A | 1 |
| Boden, KT | 1 |
| Dimopoulos, S | 1 |
| Bemme, S | 1 |
| Tamm, S | 1 |
| Maier, M | 1 |
| Roider, J | 1 |
| Enders, P | 1 |
| Altay, L | 1 |
| Fauser, S | 2 |
| Kirchhof, B | 2 |
| Kono, T | 1 |
| Miyata, R | 1 |
| Yoshimatsu, K | 1 |
| Koike, T | 1 |
| Shiozawa, S | 1 |
| Hanada, M | 1 |
| Ajihara, T | 1 |
| Naritomi, T | 1 |
| Fukuya, Y | 1 |
| van Overdam, KA | 1 |
| Sebag, J | 2 |
| Felsch, M | 1 |
| Zarrouk, M | 1 |
| Sundaram, V | 2 |
| Barsam, A | 2 |
| Virgili, G | 2 |
| Chiquet, C | 1 |
| Rouberol, F | 1 |
| Pérez-Alvarez, MJ | 1 |
| Arriola-Villalobos, P | 1 |
| Reche-Frutos, J | 1 |
| García-Sánchez, J | 1 |
| Wickham, L | 3 |
| Ho-Yen, GO | 1 |
| Bunce, C | 5 |
| Wong, D | 5 |
| Charteris, DG | 5 |
| Cardillo, JA | 1 |
| Farah, ME | 1 |
| Mitre, J | 1 |
| Morales, PH | 1 |
| Costa, RA | 1 |
| Melo, LA | 1 |
| Kuppermann, B | 1 |
| Jorge, R | 1 |
| Ashton, P | 2 |
| Aylward, GW | 2 |
| Groenewald, C | 1 |
| Asaria, RH | 2 |
| McGurn, D | 1 |
| Blumenkranz, MS | 1 |
| Ophir, A | 6 |
| Claflin, AJ | 1 |
| Hajek, A | 1 |
| Sunalp, M | 1 |
| Sorgente, N | 1 |
| Ryan, SJ | 1 |
| Blumenkranz, M | 3 |
| Hernandez, E | 3 |
| Norton, EW | 1 |
| Stern, WH | 1 |
| Lewis, GP | 1 |
| Erickson, PA | 1 |
| Guerin, CJ | 1 |
| Anderson, DH | 1 |
| Fisher, SK | 1 |
| O'Donnell, JJ | 1 |
| Rubsamen, PE | 1 |
| Davis, PA | 1 |
| O'Grady, GE | 1 |
| Cousins, SW | 1 |
| Ward, T | 1 |
| Hartzer, M | 1 |
| Lin, LR | 1 |
| Berger, AS | 1 |
| Cheng, CK | 1 |
| Pearson, PA | 1 |
| Crooks, PA | 1 |
| Cynkowski, T | 1 |
| Cynkowska, G | 1 |
| Jaffe, GJ | 1 |
| Kon, CH | 1 |
| Khaw, PT | 1 |
| Ticho, U | 1 |
| Orr, G | 1 |
| Tervaert, DC | 1 |
| Lean, JS | 1 |
| Jarus, G | 1 |
| Sossi, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.[NCT02834559] | Phase 3 | 326 participants (Actual) | Interventional | 2016-10-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluorouracil and Retinal Detachment
| Article | Year |
|---|---|
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Intravitreal Injections; Postoperative Complica | 2013 |
[Proliferative vitreoretinopathy: prophylactic treatment].
Topics: Antibiotics, Antineoplastic; Colchicine; Daunorubicin; Fibrinolytic Agents; Fluorouracil; Glucocorti | 2014 |
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Injections, Intraocular; Postoperative Complica | 2010 |
8 trials available for fluorouracil and Retinal Detachment
| Article | Year |
|---|---|
Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
Topics: Dalteparin; Double-Blind Method; Fluorouracil; Heparin; Heparin, Low-Molecular-Weight; Humans; Retin | 2022 |
Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141).
Topics: Fluorouracil; Heparin; Humans; Retinal Detachment; Vitreoretinopathy, Proliferative | 2023 |
Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
Topics: Data Interpretation, Statistical; Double-Blind Method; Endpoint Determination; Fluorouracil; Heparin | 2018 |
Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes.
Topics: Aged; Aged, 80 and over; Disease Progression; Drug Therapy, Combination; Female; Fibrinolytic Agents | 2011 |
Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure.
Topics: Adult; Aged; Antimetabolites; Female; Fibrinolytic Agents; Fluorouracil; Follow-Up Studies; Heparin, | 2011 |
A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
Topics: Aged; Antimetabolites; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; | 2004 |
Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy.
Topics: Combined Modality Therapy; Cryotherapy; Dalteparin; Double-Blind Method; Drug Therapy, Combination; | 2007 |
Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; | 2001 |
17 other studies available for fluorouracil and Retinal Detachment
| Article | Year |
|---|---|
[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2022 |
[Choroidal metastasis from a breast carcinoma. Diagnosis and follow-up with optical coherence tomography and fluorescein angiography and autofluorescence with HRA-II (Heidelberg Retina Angiograph)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2009 |
An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biodegradation, Environmental; Disease Models, Ani | 2004 |
Fluorouracil for the treatment of massive periretinal proliferation.
Topics: Animals; Cells, Cultured; Fibroblasts; Fluorouracil; Neovascularization, Pathologic; Rabbits; Retina | 1982 |
Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Doxorubicin; Eye Diseases; Female; Fibroblas | 1984 |
Prevention of experimental massive peri-retinal proliferation by 5-fluoro-uracil.
Topics: Animals; Fibroblasts; Fluorouracil; Humans; Methotrexate; Rabbits; Retinal Detachment; Vitreous Body | 1983 |
5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite.
Topics: Adolescent; Adult; Aged; Animals; Cell Division; Cells, Cultured; Female; Fluorouracil; Humans; Male | 1984 |
Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy.
Topics: Animals; Autoradiography; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Eye | 1983 |
Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil.
Topics: Animals; Biodegradation, Environmental; Chromatography, High Pressure Liquid; Delayed-Action Prepara | 1994 |
A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring.
Topics: Animals; Cell Division; Cells, Cultured; Disease Models, Animal; Eye Diseases; Fibroblasts; Fluorour | 1993 |
Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Topics: Animals; Antimetabolites; Delayed-Action Preparations; Dexamethasone; Disease Models, Animal; Drug C | 1996 |
Shaken not stirred.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Heparin, Low-Molecular-Weight; Hu | 2001 |
Trabeculectomy with 5-fluorouracil subsequent to circular buckling operation and cataract extraction.
Topics: Adult; Aged; Atropine; Cataract Extraction; Female; Fluorouracil; Follow-Up Studies; Glaucoma, Open- | 1992 |
Effects of 5-fluorouracil on proliferating fibroblasts in vivo.
Topics: Animals; Cell Division; Cells, Cultured; Fibroblasts; Fluorouracil; Microscopy, Electron; Rabbits; R | 1991 |
Further observations on the prevention of experimental proliferative vitreo-retinopathy by 5-fluorouracil.
Topics: Animals; Disease Models, Animal; Eye Diseases; Fibroblasts; Fluorouracil; Follow-Up Studies; Rabbits | 1991 |
Aqueous concentrations of fluorouracil after intravitreal injection. Normal, vitrectomized, and silicone-filled eyes.
Topics: Animals; Anterior Chamber; Aqueous Humor; Cornea; Eye; Fluorouracil; Postoperative Complications; Ra | 1986 |
Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes.
Topics: Animals; Aphakia; Fluorouracil; Injections; Metabolic Clearance Rate; Rabbits; Retinal Detachment; V | 1985 |